Taggatz Stock Market Advisory - Applied Therapeutics

Mark Taggatz, CEO of Taggatz Stock Market Advisory provides commentary for Nasdaq listed Applied Therapeutics.
 
SAN DIEGO - Dec. 5, 2019 - PRLog -- Applied Therapeutics (APLT) set a new 52 week high by closing at $24.00 on Wednesday.

Applied Therapeutics
was up $4.28

Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy.

The company's preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology.

Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.

Disclaimer: The following information from Taggatz Stock Market Advisory is for informational purposes only and is not an offer to buy or sell securities. Taggatz Stock Market is not a FINRA broker-dealer or Registered Investment Advisor. Taggatz Stock Market advisory does not own stock in any of the companies mentioned in this release. Taggatz Stock Market Advisory has not been paid by any of the companies mentioned in this release.

Contact
Mark Taggatz
***@wsmgadvisors.com
858-800-2974
End
Email:***@wsmgadvisors.com Email Verified
Tags:Stocks
Industry:Investment
Location:San Diego - California - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse



Like PRLog?
9K2K1K
Click to Share